St. John Health System

Summary

St. John Health System is a medical facility located in Tulsa, Oklahoma. This center is recognized for care of Stroke, Prostate Cancer, Brain Tumor, Head and Neck Cancers, Coronavirus and other specialties. St. John Health System is involved with conducting 73 clinical trials across 95 conditions. There are 6 research doctors associated with this hospital, such as Anuj Malik, MD, Nicholas Hanna, MD, Errol Gordon, MD, and Rahul Rahangdale, MD.

Top PIs

Clinical Trials running at St. John Health System

Stroke

Atrial Fibrillation

Bleeding

Hemorrhage

Ischemic Injury

Angina Pectoris

Chronic Angina

Anticoagulation + Antiplatelet Therapy

for Post-Operative Atrial Fibrillation

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.

Recruiting

2 awards

Phase 3

2 criteria

Recombinant Factor VIIa

for Hemorrhagic Stroke

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include only those treated within 2 hours with a positive spot sign on a baseline CT angiogram.

Recruiting

1 award

Phase 3

2 criteria

Apixaban vs Aspirin

for Stroke Prevention in Atrial Fibrillation After Brain Bleed

Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.

Recruiting

1 award

Phase 3

6 criteria